Abstract
Over the past decade the application of pharmacokinetic data in drug development has gradually increased. Today it is well recognized that successful drug development programs include meaningful supportive pharmacokinetic data. An effective pharmacokinetic program begins at the preclinical phase with well defined objectives to support pharmacology/toxicology programs, to determine effective/toxic blood concentration ranges and to help in expediting early phase I studies in man. The clinical pharmacokinetic program may be classified as follows: i) pharmacokinetics during safety and tolerance studies in man to determine key pharmacokinetic parameters including linearity over the utilized dose range, and related effective and toxic blood concentrations; ii) pivotal pharmacokinetic studies to determine metabolism profile and major active/inactive metabolite(s) in man, extent of first-pass metabolism, absolute and/or relative bioavailability, effect of food on absorption, dose proportionality, route and mechanism of elimination, bioequivalency of final dosage forms and to establish therapeutic dosing regimens; and iii) studies supporting labeling to determine pharmacokinetics in special populations, effect of disease states and interactions with concomitantly administered drugs. A successful pharmacokinetic program is done prospectively to support the design of safety evaluation studies, to assist in expediting the Phase I/II programs, and to facilitate the Phase III trials in patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barry, H., and A. Yacobi (1984). Preclinical toxicokinetics. In A. Yacobi and H. Barry, III, (Eds.), Experimental and Clinical Toxicokinetics. American Pharmaceutical Association, APS, Washington, pp. 1–7.
Batra, V. K., and A. Yacobi (1989). An overview of toxicokinetics. In A. Yacobi, J. P. Skelly and V. K. Batra, (Eds.), Toxicokinetics and New Drug Development Pergamon Press, New York, pp. 1–20.
Boxenbaum, H. (1984). Interspecies scaling, allometry, physiological time and ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10, 201–227.
Campbell, D. B., and R. M. Ings (1988). New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicol. 7, 469–479.
Collins, J. M., C. K. Grieshaber, B. A. Grieshaber, and B. A. Chadner (1990). Pharmacologically guided Phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82, 1321–1326.
Collins, J. M., D. S. Zaharko, R. L. Dedrick, and B. A. Chabner (1986). Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treatment Reports 70, 73–80.
de la Iglesia, F. A., and P. Greaves (1989). Role of toxicokinetics in drug safety evaluations. In A. Yacobi, J. P. Skelly and V. K. Batra, (Eds.) Toxicokinetics and New Drug Development. Pergamon Press, New York, pp. 21–32.
Echizen, H., B. Vogelgesang, and M. Eichelbaum (1985a). Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin. Pharmacol. Ther. 38, 71–76.
Echizen, H., T. Brecht, S. Niedergasass, B. Vogelgesang, and M. Eichelbaum (1985b). The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Amer. Heart J. 109, 210–217.
Eichelbaum, M., and A. Somogyi (1984). Inter-and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Eur. J. Clin. Pharmacol. 26, 47–53.
Eichelbaum, M., G. Mikus, and B. Vogelgesang (1984). Pharmacokinetics of (+)-, (-)- and (+)-verapamil after intravenous administration. Br. J. Clin. Pharmacol. 17, 453–458.
Fabre, G., J. Combalbert, Y. Berger, and J. P. Cano (1990). Human hepatocytes as a key in-vitro model to improve preclinical drug development. Eur. J. Drug Metab. Pharmacokinet. 15, 165–171.
Gianni, L., L. Vigano, A. Surbone, D. Ballinari, P. Casali, C. Tarella, J. M. Collins, and G. Bonadonna (1990). Pharmacology and clinical toxicity of 4’-iodo-4’- deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in Phase I trials. J. Natl. Cancer Inst. 82, 469–477.
Mordenti, J., and W. Chappel (1989). The use of interspecies scaling in toxicokinetics. In A. Yacobi, J.P. Skelly, and V.K. Batra (Eds.), Toxicokinetics and New Drug Development Pergamon Press, New York, pp. 42–96.
Rahmani, R., B. Richard, G. Fabre, and J. P. Cano (1988). Extrapolation of preclinical pharmacokinetic data to therapeutic drug use. Xenobiotica 18 (Suppl.), 71–88.
Yacobi, A., R. W. Krasula, and C. M. Lai (1984). Selective disposition studies in drug safety evaluation. In A. Yacobi and H. Barry, III, (Eds.), Experimental and Clinical Toxicok-inetics. American Pharmaceutical Association, APS, Washington, pp. 47–73.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yacobi, A. et al. (1993). Implementation of an Effective Pharmacokinetics Research Program in Industry. In: Yacobi, A., Skelly, J.P., Shah, V.P., Benet, L.Z. (eds) Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1520-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1520-0_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1522-4
Online ISBN: 978-1-4757-1520-0
eBook Packages: Springer Book Archive